Saiba AG focuses on a future COVID-19 vaccine with advantages over first to market vaccine candidates
Saiba AG has decided to focus on optimization of its vaccine candidate rather than rush into clinical studies in 2020.
Read MoreSaiba AG has decided to focus on optimization of its vaccine candidate rather than rush into clinical studies in 2020.
Read MoreSaiba proprietary technology has enabled scientists to generate a vaccine candidate against COVID-19 with preclinical proof-of-concept.
Read More